Markets › United States › Vertex Pharmaceuticals
Vertex Pharmaceuticals (VRTX) share price
515.02 USD -1.08%
NasdaqGS · last price Fri 20 Nov, 16:00 local time · change vs previous close · may be delayed
Why is Vertex Pharmaceuticals moving?
Vertex shares fell 1.08% today and are down 4.4% over the past week, but none of the headlines provided explain this move, so it came without obvious company-specific news and may reflect the wider market or sector. The stock is still up 13.6% year to date and 20.7% over the past year.
- The shares closed at $515.02, about $53.65 below their 52-week high of $568.67 and $102.75 above their 52-week low of $412.27.
- The one-month decline of 3.8% is shown without any linked event in the data.
- The most company-specific headline, the $220m extension of the Genomics drug discovery alliance, does not mention any effect on the share price.
AI-generated from price data and headlines. May contain errors. Not advice.
Open Vertex Pharmaceuticals in the live dashboard →
Vertex Pharmaceuticals share price over the past year
Key figures
| Previous close | 520.66 USD |
| Day range | 513.80 – 531.37 |
| 52-week range | 412.27 – 568.67 |
| 1 week | -4.38% |
| 1 month | -3.77% |
| Year to date | +13.60% |
| 1 year | +20.68% |
| Volume | 1.77M |
| Currency | USD |
Latest Vertex Pharmaceuticals news
- Is It Too Early To Buy Insmed Stock? Trefis · 20 Nov
- Has Vertex Stock Become A Different Bet? Trefis · 20 Nov
- 2 Growth Stocks to Buy in November Without Any Hesitation Motley Fool · 19 Nov
- Genomics, Vertex extend drug discovery alliance in $220m deal Pharmaceutical Technology · 19 Nov
- Should You Pick Vertex Stock Over Its Biotech Rivals? Trefis · 18 Nov
- The Women’s Edge and The Boston Globe Again Name CCC to Top 100 Women-Led Businesses in Massachusetts List GlobeNewswire · 18 Nov
Other big United States stocks
NVIDIA Apple Microsoft Broadcom Oracle AMD Salesforce Cisco IBM ServiceNow Accenture Adobe
General information only, not financial advice. Prices from Yahoo Finance and may be delayed.